Description of an in vitro platelet function analyzer--PFA-100.

abstract：:Eradication of factor VIII (FVIII) specific neutralizing antibodies (also known as inhibitors) by the traditional method of immune tolerance induction (ITI) is costly and unsuccessful in one out of three patients. Furthermore, effective inhibitor prevention strategies are presently lacking. An overview is given in thi...

journal_title：Seminars in thrombosis and hemostasis

authors： Hassan S,Fijnvandraat K,van der Bom JG,Gouw SC

更新日期：2018-09-01 00:00:00

abstract：:Patients undergoing surgery for malignancy are at increased risk of initial and recurrent venous thromboembolism (VTE). Several factors have been found to increase the risk of deep vein thrombosis (DVT) in cancer patients both during the first days after the operation and after discharge from hospital. Although, in ge...

journal_title：Seminars in thrombosis and hemostasis

authors： Khushal A,Quinlan D,Alikhan R,Gardner J,Bailey C,Cohen A

更新日期：2002-12-01 00:00:00

abstract：:Available data suggest that elevated triglyceride levels in plasma, associated with increased VLDL or chylomicron remnants, are associated with premature coronary artery atherosclerosis. Whether this is a direct effect or as a result of the association of hypertriglyceridemia with decreased HDL as well as decreased LD...

journal_title：Seminars in thrombosis and hemostasis

authors： Schaefer EJ,McNamara JR,Genest J Jr,Ordovas JM

更新日期：1988-04-01 00:00:00

abstract：:Oral anticoagulants (OAs) are the drugs of choice for the prevention of recurrence and death in patients with venous thromboembolism (VTE). Oral anticoagulant treatment (OAT) aims to retard blood coagulation to obtain maximum protection against thromboembolic events with the lowest risk of bleeding. The intensity of O...

journal_title：Seminars in thrombosis and hemostasis

authors： Pengo V

更新日期：2006-11-01 00:00:00

abstract：:The catastrophic variant of the antiphospholipid syndrome (APS) is a condition characterized by multiple vascular occlusive events, usually affecting small vessels and evolving over a short period of time, together with laboratory confirmation of the presence of antiphospholipid antibodies. The pathogenesis of catastr...

journal_title：Seminars in thrombosis and hemostasis

authors： Espinosa G,Bucciarelli S,Asherson RA,Cervera R

更新日期：2008-04-01 00:00:00

abstract：:Patients with end-stage renal disease suffer from complex hemostatic disorders. Uremic patients show a bleeding diathesis that is mainly due to abnormalities of primary hemostasis; in particular, platelet dysfunction and impaired platelet-vessel wall interaction. However, despite decreased platelet function, these pat...

journal_title：Seminars in thrombosis and hemostasis

authors： Boccardo P,Remuzzi G,Galbusera M

更新日期：2004-10-01 00:00:00

abstract：:A series of sulfated bis-lactobionic acid amides was prepared. The compounds comprise highly charged poly-anions of very low molecular weight. Usually, the compounds contain 16 sulfate groups per molecule and are homogeneous, monodisperse substances. The molecular weights range from 2388 to 2514. The compounds were ev...

journal_title：Seminars in thrombosis and hemostasis

authors： Klauser RJ,Meinetsberger E,Raake W

更新日期：1991-01-01 00:00:00

abstract：:Development of inhibitory antibodies (inhibitors) to factor VIII (FVIII) is the most serious adverse event in replacement therapy of hemophilia A patients. The etiology and management of this condition remain major challenges for both researchers and clinicians. In the present review, we discuss recent advances in und...

journal_title：Seminars in thrombosis and hemostasis

authors： Ananyeva NM,Lee TK,Jain N,Shima M,Saenko EL

更新日期：2009-11-01 00:00:00

abstract：:In order to assess inhibitor development in previously untreated patients (PUPs) with severe (factor VIII [FVIII]<1%) and moderate (FVIII 1 to 5%) hemophilia A, a prospective study was initiated in 1976. During the 23-year study period, 72 hemophiliacs were frequently exposed prophylactically or on demand to plasma-de...

journal_title：Seminars in thrombosis and hemostasis

authors： Kreuz W,Ettingshausen CE,Zyschka A,Oldenburg J,Saguer IM,Ehrenforth S,Klingebiel T

更新日期：2002-06-01 00:00:00

abstract：:It is generally accepted that the initial event in coagulation and intravascular thrombus formation is the exposure of the flowing blood to cell-surface protein, such as tissue factor (TF). Vascular injury and/or atherosclerotic plaque complication is responsible for this exposure, leading to clinical manifestations s...

journal_title：Seminars in thrombosis and hemostasis

authors： Cimmino G,Ciccarelli G,Golino P

更新日期：2015-10-01 00:00:00

abstract：:In order to obtain a global assessment of circulating clopidogrel-related products and of the excretion of the drug, the pharmacokinetic behavior and the excretion balance of 14C radioactivity following the administration of a single dose of 75 mg of 14C-labeled clopidogrel were compared in 6 clopidogrel-free healthy ...

journal_title：Seminars in thrombosis and hemostasis

authors： Lins R,Broekhuysen J,Necciari J,Deroubaix X

更新日期：1999-01-01 00:00:00

abstract：:Heparanase is an endo-β-glucuronidase that enzymatically cleaves heparan sulfates (HS) and heparan sulfate proteoglycan (HSPG) structures. Heparanase expression levels by tumors were correlated with cell invasion, angiogenic activity, and poor prognosis. Heparanase can also possess pro-tumorigenic effects independent ...

journal_title：Seminars in thrombosis and hemostasis

authors： Gerber U,Hoß SG,Shteingauz A,Jüngel E,Jakubzig B,Ilan N,Blaheta R,Schlesinger M,Vlodavsky I,Bendas G

更新日期：2015-03-01 00:00:00

abstract：:A prospective randomized double-blind trial was performed comparing conventional low-dose heparin with a LMWH fragment (Kabi 2165, Fragmin) for thromboprophylaxis in elective general abdominal surgical patients. The first dose of the fragment was given in the evening before surgery, and thereafter every evening. There...

journal_title：Seminars in thrombosis and hemostasis

authors： Bergqvist D,Burmark US,Frisell J,Guilbaud O,Hallböök T,Horn A,Lindhagen A,Ljungner H,Ljungström KG,Mätzsch T

更新日期：1990-10-01 00:00:00

abstract：:Atrial fibrillation (AF) can be secondary to acute pulmonary embolism (PE). This study aimed to investigate the prognostic impact of new-onset AF on patients with acute PE. In this study, 4,288 consecutive patients who were diagnosed with acute PE were retrospectively screened. In total, 77 patients with acute PE and ...

journal_title：Seminars in thrombosis and hemostasis

authors： Tang RB,Jing YY,Xu ZY,Dong JZ,Du X,Wu JH,Yu RH,Long DY,Ning M,Sang CH,Jiang CX,Bai R,Liu N,Wen SN,Li SN,Chen X,Huang ST,Cui YK,Ma CS

更新日期：2020-11-01 00:00:00

abstract：:In the pathogenesis of vascular disease, inflammation and coagulation play a pivotal role. Increasing evidence points to an extensive cross-talk between these two systems, whereby inflammation not only leads to activation of coagulation, but coagulation also considerably affects inflammatory activity. Tissue factor (T...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M,van der Poll T,ten Cate H

更新日期：2006-02-01 00:00:00

abstract：:Platelet-dependent thrombosis is an important part of the pathophysiology of both percutaneous coronary interventions (PCI) and acute coronary syndrome (ACS). Data support the use of acute therapies that interfere with platelets to provide clinical benefit to patients presenting with acute cardiovascular disease. The ...

journal_title：Seminars in thrombosis and hemostasis

authors： Harrington RA

更新日期：2004-12-01 00:00:00

abstract：:While lupus anticoagulant (LA), anticardiolipin antibodies (aCL), anti-β2 glycoprotein I (anti-β2GPI) antibodies represent the best available and the most widely used tests in the investigation for antiphospholipid syndrome (APS), evidence gathered in recent years indicates that other antiphospholipid antibodies (aPL)...

journal_title：Seminars in thrombosis and hemostasis

authors： Bertolaccini ML,Sanna G

更新日期：2018-07-01 00:00:00

abstract：:Coagulation management requires the balancing of different components that contribute to clot formation. These components include the interactions between platelets, procoagulant, anticoagulant, and fibrinolytic factors. The cause of bleeding or thrombotic events is often multifactorial; however, the tests clinicians ...

journal_title：Seminars in thrombosis and hemostasis

authors： Wegner J,Popovsky MA

更新日期：2010-10-01 00:00:00

abstract：:Biological rhythms are a universal phenomenon in living organisms and serve to help organisms adapt within a circadian cycle to the 24-hour-oscillating environment. The rhythmic modulation of selective pathways thus enables organisms to optimize their ability to store and generate chemical energy, to minimize environm...

journal_title：Seminars in thrombosis and hemostasis

authors： Montagnana M,Salvagno GL,Lippi G

更新日期：2009-02-01 00:00:00

abstract：:We have explored the molecular basis of the clinical therapeutic effect of factor VIIa in hemophilia A using empirical reconstituted in vitro thrombin generation models. Tissue factor acts as a receptor and activator of preexistent but virtually inactive two-chain plasma factor VIIa. However, most of the factor VII ci...

journal_title：Seminars in thrombosis and hemostasis

authors： van't Veer C,Mann KG

更新日期：2000-01-01 00:00:00

abstract：:The increased prevalence of the laboratory diagnosis of von Willebrand disease (vWD) in women presenting with menorrhagia has raised concerns regarding certain specifics in vWD testing in women, including when vWD testing should be done in relation to menses and whether testing should be done while the patient is not ...

journal_title：Seminars in thrombosis and hemostasis

authors： Kouides PA

更新日期：2006-07-01 00:00:00

abstract：:Cancer often leads to the activation of coagulation, manifesting as disseminated intravascular coagulation (DIC) in its most extreme form. DIC is characterized by systemic intravascular coagulation activation (leading to deposition of intravascular platelets and fibrin) and simultaneous consumption of coagulation prot...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M

更新日期：2019-06-01 00:00:00

abstract：:Approximately 5 to 7% of patients with hemophilia A have inhibitory antibodies to factor (F) VIII, which increases to approximately 13% in patients with severe disease. The strongest determinant of the risk of inhibitor development identified is the type of mutation in the FVIII gene that gives rise to the disease. Ho...

journal_title：Seminars in thrombosis and hemostasis

authors： Lee CA,Lillicrap D,Astermark J

更新日期：2006-06-01 00:00:00

abstract：:A simple nonisotopic method for the quantitation of FPA in biologic samples has been developed utilizing a competitive enzyme immunoassay technique. The performance characteristics of these assays have been investigated in both the experimental and clinical settings and were found to be satisfactory for the routine cl...

journal_title：Seminars in thrombosis and hemostasis

authors： Amiral J,Walenga JM,Fareed J

更新日期：1984-10-01 00:00:00

abstract：:Severe acute inflammation in chronic inflammatory bowel disease is associated with large wound areas and ulcerations that show spontaneous hemorrhage or marked friability. Therefore, an enormous potential of hemostasis and wound healing is required. Coagulation studies demonstrate a deficiency of factor XIII that is i...

journal_title：Seminars in thrombosis and hemostasis

authors： Lorenz R,Olbert P,Born P

更新日期：1996-01-01 00:00:00

abstract：:Recently it was reported that chorionic villous hemorrhage (CVH) had a significant association with retroplacental hemorrhage (RPH). In this study, to determine whether CVH has a correlation with RPH or intervillous thrombosis (IVT), placentas associated with CVH were clinico-histopathologically investigated and compa...

journal_title：Seminars in thrombosis and hemostasis

authors： Soma H,Watanabe Y,Osawa H,Hata T

更新日期：1998-01-01 00:00:00

abstract：:Thrombophilia can be defined as an increased tendency to thrombosis. There are several defined risk factors for thrombosis, and these are generally separated into acquired and congenital factors. Congenital risk factors include deficiencies or defects in natural anticoagulants, such as antithrombin, protein C and prot...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ

更新日期：2005-02-01 00:00:00

abstract：:Acute promyelocytic leukemia (APL), once highly fatal, has emerged as the most curable subtype of acute myeloid leukemia in adults. Cure is now expected in approximately 70 to 90% of patients when treatment includes all- TRANS retinoic acid (ATRA) combined with anthracycline-based chemotherapy. Early mortality most of...

journal_title：Seminars in thrombosis and hemostasis

authors： Tallman MS,Abutalib SA,Altman JK

更新日期：2007-06-01 00:00:00

abstract：:Life expectancy for persons with hemophilia (PWH) has considerably increased in the last decades as a direct result of the availability of modern therapies to control the clotting defect. Because their life expectancy now matches that of the general population, PWH are experiencing age-related comorbidities, such as, ...

journal_title：Seminars in thrombosis and hemostasis

authors： Coppola A,Santoro C,Franchini M,Mannucci C,Mogavero S,Molinari AC,Schinco P,Tagliaferri A,Santoro RC

更新日期：2013-10-01 00:00:00

abstract：:There is a persuasive body of evidence suggesting that tissue factor (TF) is a major determinant of tumor progression. In addition to its "traditional" function as the initiator of hemostasis, TF may support tumor progression through signaling mechanisms involving either direct signal transduction through the TF cytop...

journal_title：Seminars in thrombosis and hemostasis

authors： Palumbo JS

更新日期：2008-03-01 00:00:00